Investigation of the autoimmune diseases pathogenesis through microRNA exhaustive analysis
Project/Area Number |
26860265
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Experimental pathology
|
Research Institution | Juntendo University |
Principal Investigator |
Hayakawa Kunihiro 順天堂大学, 医学(系)研究科(研究院), 博士研究員 (00573007)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | miRNA / 関節リウマチ / 全身性エリテマトーデス / 炎症 / 自己免疫疾患 / 炎症応答 / SLE |
Outline of Final Research Achievements |
Rheumatoid arthritis (RA) and systemic lupus erythematosus are typical autoimmune disease. In this study, we revealed the microRNA (miRNA) is associated with these disease activities. In the study targeting of RA, we first performed miRNA array analysis of plasma from patient with before and after treatment of abatacept, and identified the fluctuated miRNA between before and after treatment. Next, we intended to investigate the influence of these miRNAs in RA disease activity, and tested to confirm inflammatory responses using RA synoviocyte. Interestingly, up-regulated miRNAs by treatment have anti-inflammatory effect. Conversely, down-regulated miRNAs showed effect to increase inflammation. That is, plasma miRNA from high activity RA patients may contribute the sustention of disease activity, and plasma miRNA in low activity RA patients may conversely assist the suppression of inflammation.
|
Report
(4 results)
Research Products
(11 results)
-
[Journal Article] The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.2017
Author(s)
Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I
-
Journal Title
Clin Rheumatol
Volume: 36
Issue: 1
Pages: 51-58
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
[Journal Article] Inhibition of each module of connective tissue growth factor as a potential therapeutic target for rheumatoid arthritis.2015
Author(s)
Miyashita T, Morimoto S, Fujishiro M, Hayakawa K, Suzuki S, Ikeda K, Miyazawa K, Morioka M, Takamori K, Ogawa H, Sekigawa I, Takasaki Y.
-
Journal Title
Autoimmunity
Volume: 49(2)
Issue: 2
Pages: 109-14
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis.2014
Author(s)
Suzuki S, Morimoto S, Fujishiro M, Kawasaki M, Hayakawa K, Miyashita T, Ikeda K, Miyazawa K, Yanagida M, Takamori K, Ogawa H, Sekigawa I, Takasaki Y
-
Journal Title
Autoimmunity
Volume: -
Issue: 4
Pages: 251-8
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-